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Abstract
Objectives: To report the results of the Nit-Occlud PDA prospective postapproval study (PAS)
along with a comparison to the results of the pivotal and continued access trials.
Background: The Nit-Occlud PDA (PFM Medical, Cologne, Germany), a nitinol coil patent duc-
tus arteriosus (PDA) occluder, was approved by the Food and Drug Administration in 2013.
Methods: The PAS enrolled a total of 184 subjects greater than 6 months of age, weighing at
least 5 kg, with PDAs less than 4 mm by angiography at 11 centers. Patients were followed pro-
spectively at 2 months, 12 months, and 24 months postprocedure. These outcomes were com-
pared to the 357 subjects enrolled in the pivotal and continued access protocols. Efficacy and
safety data were reported.
Results: Among 184 subjects enrolled for the PAS between 2014 and 2017, 180 (97.8%) had
successful device implantation. After 12 months, 98.7% (150/152) had trivial or no residual
shunt by echocardiography and two subjects had only small residual shunts. There were three
Institutions where the work was performed: Multi-center study.
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device embolizations that were all retrieved by snare without clinical consequence. Together
with the pivotal and continued access study, 97.4% (449/461) had complete echocardiographic
closure at 12 months in 541 enrolled subjects. The composite success was 94.4%. There were
no mortalities and no serious device-related adverse events.
Conclusions: The Nit-Occlud PDA is a safe and effective device for closure of a small to moder-
ate sized PDA. There were no serious device-related adverse events in a large cohort of three
clinical trials.
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1 | INTRODUCTION
Patent ductus arteriosus (PDA) is one of the common congenital heart
diseases. Transcatheter closure of PDA is indicated for medium- to
large-sized PDA and small audible PDAs.1 The Nit-Occlud PDA (PFM
Medical, Cologne, Germany) is a nitinol coil designed with two cones
of spirals specifically for use as a PDA occluder. Its premarket
approval was approved by the Food and Drug Administration in 2013
based on the results of the pivotal trial. The Nit-Occlud is currently
approved in the US for closure of PDAs smaller than 4 mm in infants
greater than 5 kg and 6 months of age. The result of the combined
United States multicenter pivotal and the continuing access study was
reported in 2014, showing the excellent efficacy and safety of the
Nit-Occlud PDA for closure of small- to medium-sized PDA.2
The Nit-Occlud PDA postapproval study (PAS) was designed to
continue to evaluate the safety and efficacy of the Nit-Occlud PDA
device in the postapproval phase. The objective of this study was to
report the results of the Nit-Occlud PDA prospective PAS along with
a comparison to the results of the pivotal and continued access trial.
2 | MATERIALS AND METHODS
2.1 | Device and procedure
The Nit-Occlud PDA device is a nitinol coil designed for PDA closure.
The device specification has been previously described in detail.2 The
Nit-Occlud PDA device has a reverse-cone shape having proximal and
distal coils that is made to fit into the ductal ampulla and anchor to
the pulmonary side of the PDA (Figure 1A). There are six sizes avail-
able: 4 × 4 mm, 5 × 4 mm, 6 × 5 mm, 7 × 6 mm, 9 × 6 mm,
11 × 6 mm. Each device is named by diameter of distal coil diame-
ter × proximal coil loop diameter. The smaller “Flexible” devices
(4 × 4 mm, 5 × 4 mm, 6 × 5 mm) can be delivered through a 4-Fr
delivery catheter, whereas the larger “Medium” devices (7 × 6 mm,
9 × 6 mm, 11 × 6 mm) require a 5-Fr delivery catheter. The size of
device is selected according to the angiographic measurement of PDA
on lateral aortography. The distal coil diameter should be no more
than 2 mm larger than the aortic ampulla diameter and at least
3–4 mm larger than the pulmonary end and/or narrowest diameter of
PDA. The length of device should not be longer than the ductal length.
The Nit-Occlud PDA device is usually deployed anterograde from the
pulmonary side. Distal windings of the device are configured in the
descending aorta (DAO) and pulled back to the ductal ampulla. Then,
one of the “reverse cone” proximal windings are delivered at the pul-
monary side. After confirming a satisfactory position of coil, the
device is detached (Figure 1B). If embolized, the device can be
retrieved by snaring any part of the coil and retracting it into a 6-Fr
sheath.
2.2 | Study design
The Nit-Occlud PAS study was a prospective, nonrandomized multi-
center trial conducted in 11 medical centers (Appendix 1) in the
United States. The study evaluated the safety and effectiveness of
the Nit-Occlud PDA device in the postapproval phase. The study's
outcomes were defined to determine whether the Nit-Occlud PDA
met or exceeded objective performance criteria (OPC) derived from
historical results of device and surgical PDA closure.3 Local institu-
tional review board approval was obtained in each participating center
for this study. Informed consent was obtained for each study subject.
Inclusion criteria were: age between 6 months and 21 years,
weight ≥ 5 kg, and an angiographically confirmed PDA with a mini-
mum diameter of <4 mm. Exclusion criteria included presence of asso-
ciated cardiac anomalies requiring surgery, bleeding or clotting
disorders, pulmonary hypertension (with pulmonary vascular resis-
tance ≥5 Woods unit), contrast or nickel allergy, pregnancy and acute
illnesses.
Patients were evaluated before and during cardiac catheteriza-
tion, at hospital discharge, and 2 months, 12 months, and 24 months
after device implant. Subjects with documented residual PDA shunt,
any significant left pulmonary artery (LPA) or DAO obstruction and/or
on ongoing device-related issue at 12 months were followed yearly
postimplant for an additional 4 years (24 months, 48 months, and
60 months). At follow-up, subjects were evaluated on history, physical
examination and transthoracic echocardiography. Subject data were
maintained in an electronic study database. The consistency of reports
with source patient data were confirmed by the periodic site audits.
2.3 | Outcome measures
The primary outcome of the PAS was effectiveness and safety at
12-month after device implant. The effectiveness measure was
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complete closure of PDA, defined as absence of residual PDA flow by
color Doppler transthoracic echocardiography. The OPC for the effec-
tiveness measure was 85%. The safety measure was serious device-
related adverse event defined as life-threatening events that required
surgery to correct, resulted in hospitalization or prolonged hospital
stay, caused long-term disability, or resulted in genetic damage or
birth defect. Other serious adverse events included cerebral or pulmo-
nary embolism, bacterial endocarditis, device embolization requiring
surgery, and persistent cardiac arrhythmia requiring a pacemaker.
Total adverse events included serious adverse events and non-life
threatening events, which were resolved either by nonsurgical inter-
vention or with no intervention. The OPC for serious device-related
adverse events was 1%. Composite success was defined as technical
success of device implantation, clinical and echocardiographic closure
of the PDA 1 year after device implantation, and absence of device-
or procedure related death or serious device-related adverse events
after 1 year follow-up. The OPC for the composite success was 80%.
In addition, these outcome measures were evaluated in the combined
cohort of the pivotal, continued access and postapproval studies.
2.4 | Statistical analysis
Data were expressed as frequency (percentage) for binary outcomes.
Standard errors and exact 95% confidence intervals were calculated.
Statistical analysis was performed using the statistical softwares
including SAS (SAS Institute Inc., Cary, North Carolina) and STATA
(version 10, StataCorp, College Station, Texas) and StatXact software
(Cytel Software, Cambridge, Massachusetts). Outcome measures were
compared with OPC.
3 | RESULTS
A total of 184 subjects were enrolled from 11 sites in the PAS
(Figure 2). The median age of patients was 3.4 years (range 4 months
FIGURE 1 A, Nit-Occlud PDA coil. B, Descending aortography at the straight lateral projection. Baseline angiography (left) shows type A ductus
arteriosus with moderate left to right shunt. After implantation of Nit-Occlud PDA coil, angiography (right) demonstrates a satisfactory position of
Nit-Occlud PDA coil within the ductus arteriosus, resulting in no residual shunt [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 2 Study flow chart in the postapproval study
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to 21.1 years) with median weight of 14.1 kg (range 5.5–86.9 kg).
Female patients constituted 68.5% (126/184) of the subjects. Addi-
tional congenital heart diseases were present in 23.9% of the patients
(44/184), most commonly interatrial communication. The majority
(92.9%) of patients had an audible PDA murmur. Thirteen patients
had PDAs without an audible murmur (Table 1).
The median minimum PDA diameter was 1.7 mm (range 0.6 mm–
3.6 mm) with median PDA length of 8.0 mm (range 2.5 mm–21.9 mm).
PDA was classified angiographically as Krichenko4 type A (conical)
83.7%, type B (short) 1.1%, type C (tubular) 2.2%, type D (complex)
3.3%, and type E (elongated) 9.8% (Table 1).
Successful implantation was achieved in 180 of 184 patients
(97.8%). There were four technical failures (2.2%), which were attrib-
uted to a larger ductal size in three and premature release of device in
TABLE 1 General characteristics of subjects enrolled in the
postapproval study
Characteristics N = 184
Gender – n (%)
Female 126 (68.5%)
Male 58 (31.5%)
Age (years) at enrollment
Median [IQR] 3.4 [1.5, 5.4]
Range 0.3–21.1
Weight (kg) at enrollment
Median [IQR] 14.1 [9.9, 20.8]
Range 5.5–86.9
History of congenital heart
disease other than PDA – n (%)
44 (23.9%)
Atrial septal defect (ASD) 9 (4.9%)
ASD/PFO 1 (0.5%)
ASD/ventricular septal defect (VSD) 1 (0.5%)
ASD/PFO/coarctation of the aorta (CoA) 1 (0.5%)
ASD/PFO/valve stenosis 1 (0.5%)
ASD/VSD/valve stenosis 1 (0.5%)
Bicuspid aortic valve 2 (1.1%)
Cardiomyopathy 1 (0.5%)
Mitral regurgitation 1 (0.5%)
Patent foramen Ovale (PFO) 10 (5.4%)
Perimembranous (PM) vs. supracristal VSD 1 (0.5%)
PFO/aortic arch narrowing 1 (0.5%)
PFO/valve insufficiency 1 (0.5%)




operations – n (%)
2 (1.1%)
Continuous murmur consistent with PDA
Present on auscultation – n (%)
Yes 171 (92.9%)
No 13 (7.1%)
PDA sizea N = 184
Minimum diameter (mm)
Median [IQR] 1.7 [1.3, 2.1]
Range 0.6–3.6
Aortic diameter (mm)
Mean  SD 8.0  2.5
Range 1.3–14.9
Length (mm)
Median [IQR] 8.0 [6.3, 9.9]
Range 2.5–21.9
PDA type – n (%)
Conical (type A) 154 (83.7%)
Short (type B) 2 (1.1%)
Tubular (type C) 4 (2.2%)
Complex (type D) 6 (3.3%)
Elongated (type E) 18 (9.8%)
a Determined prior to device implant with aortogram.
TABLE 2 Procedure characteristics for the implant surgery of the
postapproval study
Successful implant – n (%) N = 184
Yes 180 (97.8%)
No 4 (2.2%)
Total fluoroscopy time (min) N = 184
Median [IQR] 11.0 [8, 17]
Range 4–136
Duration of surgery in minutes N = 174a
Median [IQR] 52.5 [37, 76]
Range 4–190
Sedation or anesthesia type – n (%) N = 184
General 120 (65.2%)
General with local 47 (25.5%)
Conscious sedation 16 (8.7%)
None noted 1 (0.5%)




PDA approachc – n (%) N = 180
Venous (antegrade) 172 (95.6%)
Arterial (retrograde) 8 (4.4%)
Device size implanted (mm) – n (%) N = 180
4 × 4 11 (6.2%)
5 × 4 23 (12.9%)
6 × 5 39 (21.8%)
7 × 6 53 (29.4%)
9 × 6 39 (21.8%)
11 × 6 15 (8.4%)
a N = 174 as two subjects did not have procedure start time collected,
seven subjects did not have procedure stop time collected and one sub-
ject did not have start and stop time collected.
b Per protocol, it is possible the user may attempt to implant a Nit-Occlud
PDA and realize the device is the incorrect size; this is an anticipated
occurrence and is not considered a technical failure or a protocol
deviation.
c For subjects with more than one implant attempt, data from the final
implant are used for this summary table.
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one. For the three cases in which the PDA was deemed too large for
NitOcclud closure, the device was deployed but not released. After
successful retrieval of the NitOcclud devices, non-study devices were
used to close these four PDAs. Median total fluoroscopy time was
11.0 min. The median procedure duration was 52.5 min. Of the
184 subjects enrolled, 133 were discharged the same day as the
implant procedure and the remaining 51 subjects were discharged the
day after the procedure. All procedures were performed under general
anesthesia (90.7%), or conscious sedation (8.7%). One subject's anes-
thesia type was unreported.
The device was delivered by the first attempt in 166/184 (90.2%),
and via venous (antegrade) approach in 172/184 (95.6%). The device
size implanted were 4 × 4 mm in 11 patients (6.2%), 5 × 4 mm in
23 (12.9%), 6 × 5 mm in 39 (21.8%), 7 × 6 mm in 53 (29.4%),
9 × 6 mm in 39 (21.8%) and 11 × 6 mm in 15 (8.4%) (Table 2).
3.1 | Efficacy and safety of postapproval study
Effectiveness endpoint was echocardiographic closure of PDA at
12-month postdevice implant (Table 3). This endpoint was also evalu-
ated at hospital discharge, after 2 months, and after 12 months. At
the 2-month follow-up, only 2.9% (5/170) of subjects had a small
residual PDA shunt by echocardiography. No subjects had medium or
severe residual shunt at the 2-month follow-up. At the 12-month
follow-up, 98.7% (150/152) of subjects had trivial or no residual shunt
assessed by echocardiography. Eight subjects had trivial shunt at the
12 month evaluation. The clinical closure rate (i.e., lack of a continu-
ous murmur by auscultation) was 100% (152/152). At 24-month
follow-up, 98.4% (60/61) had no detectable PDA murmur and all sub-
jects with an echocardiography (n = 30) had no or trivial residual
shunt on echocardiography.
The available data include AEs reported through the 12-month
follow-up for the subjects with successful implantation. AE data were
collected through 1-month postprocedure only for subjects that did
not receive the study device. The safety endpoint was serious device-
related adverse events at 24-months postdevice implant. However,
subjects are continuing in follow-up and only 12-month follow-up
data are currently available at this time. Despite having only
12-month data currently, the number of device related AEs by the
24-month may be minimal given there have been no late-reported
related events to date across all studies.
There were no deaths and no cases of hemolysis. There were no
subjects having significant obstruction in the LPA or DAO on echocar-
diography at 12-month follow-up, which was defined as a mean gradi-
ent >10 mmHg. Thirteen patients had 16 serious adverse events
(Table 4). None of the serious adverse events were device-related, but
three of the SAEs were probably or definitely procedure-related.
There were 6 (4.9%) device-related and 14 (11.5%) procedure-related
non-SAEs that occurred within the 12-month follow-up period.
Device-related events included three device embolizations all of
which occurred immediately following implantation (one embolized to
the main pulmonary artery, one to the left femoral artery and a third
to the abdominal aorta). In two cases, percutaneous retrieval was per-
formed during the implantation procedure and another Nit-Occlud
device was implanted successfully; the third subject was exited and a
non-study device was implanted. Additional device-related AEs were
device malposition (n = 1), and spontaneous detachment of coil from
delivery cable without embolization (n = 3). Three procedure-related
SAEs include the following: temporary loss of pulse requiring anticoa-
gulation therapy (n = 2), left vocal cord paralysis (n = 1). Loss of pulse
TABLE 3 Efficacy endpoint: echocardiographic closure of PDA at
12-month postdevice implant and additional timepoints


















a N = 170 as two subjects did not have an echocardiogram at the month
2 visit.
b N = 152 as one subject was missing residual leak data.
c Month 24 echo not required per protocol and is noted here only if site
reported the information.




Number (%) of subjects
with AE (N = 184)a
All AEs 122 77 (41.8%),
[CI =34.3%, 49.3%]
Serious 16 (13.1%) 13 (7.1%)
Non-serious 106 (86.9%) 171 (92.9%)
AEs by relationship to
device or procedureb
Procedure-related 15 (12.3%) 14 (7.6%)
Occurred ≤12-months
postprocedure
14 (11.5%) 13 (7.1%)
Device-related 6 (4.9%) 6 (3.2%)
Occurred ≤12-months
postprocedure
6 (4.9%) 6 (3.2%)
Not device or
procedure-related
102 (83.6%) 165 (89.7%)
Late onset device or
procedure-relatedc
1 (0.8%) 1 (0.5%)
a Subjects with failed implants were followed through month 1 and any
reported AEs are included.
b AEs classified as definitely or probably are considered related; AEs classi-
fied as possibly, unlikely or not related are not related.
c Late onset includes AEs that occur after the initial hospitalization for the
implant procedure.
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resolved at follow-up, whereas left vocal cord paralysis required ongo-
ing speech therapy.
The other non-serious procedure-related AEs reported through
12 months were the following: access site hematoma (n = 8), device
malposition (n = 2), inability to re-deploy device (n = 1), transient
mitral regurgitation (n = 1), and allergic skin reaction to tape (n = 1).
Among 62 subjects completing 24-month follow-up, two subjects had
late-onset procedure-related SAEs. These were both residual PDA
shunts for which the operators chose to place additional non-study
coils at 14 and 19 months post-NitOcclud implant. Composite success
accounting for procedure technical success, clinical and echocardio-
graphic closure of PDA, death, and device-related SAE at 1 year
follow-up was 92.8% (141/152).
3.2 | Combined cohort of pivotal, continued access,
and postapproval studies
Comparing with the Pivotal and Continuing Access Studies, the PAS
had comparable technical success, clinical and echocardiographic clo-
sure at 12 months (Table 5). Although there were no device- and
procedure-related SAEs in the pivotal and continued access studies,
there were three procedure-related SAEs in the PAS. As mentioned
above, two of these three SAEs were treated and resolved without
clinical consequences.
Combining the subjects from the three clinical trials of pivotal,
continued access and postapproval studies, technical success at
implantation was 97.4% (527 of 541). There were 14 technical fail-
ures. At 12-month after device implant, 466 subjects completed clini-
cal evaluation and 436 completed echocardiographic evaluation.
Clinical and complete echocardiographic closure (defined as a com-
plete absence of any shunt) at 12 months was 98.5% (460 of 467)
and 95.9% (418 of 436). There was no death. Total device-related
SAEs at 12 months was 0% (0/467) and procedure-related SAEs at
12 months was 0.6% (3/467). Composite success at 12 months was
94.4% (435/461). There were five device embolizations that were all
retrieved by snare without clinical consequence.
4 | DISCUSSION
The NitOcclud PAS study prospectively enrolled 184 patients at
11 centers. When all three of the FDA mandated clinical trials of Nit-
Occlud (pivotal, continuing access, and postmarket) were combined, a
total of 541 prospectively enrolled patients were available for analysis.
This large cohort with long-term follow-up allows for the performance
of a well powered study of the technical success, safety and efficacy
of this device. This publication reports both the PAS results as well as
an overview of the combined results of all three trials.
The primary safety endpoint of the Nit-Occlud PAS study was
assessed primarily by the rate of serious adverse events. In the PAS
and in all three studies, there were no deaths, no device-related seri-
ous adverse events and no hemolysis in any of the patients. In a total
of 461 patients, the rate of device related SAEs was 0.6%. The PAS
had five procedure-related SAEs through 24-months postimplant, of
which four were treated and resolved without clinical consequence. In
the five episodes of Nit-Occlud embolizations, the device was easily
snared and retrieved in all cases without the use of a 6–7 Fr sheath.
Furthermore, obstruction of flow in the aorta or pulmonary artery was
not seen.
The PAS also provided a third test of the Nit-Occlud PDA device's
efficacy for closure of PDA's < 4 mm in diameter. At the 12-month
follow-up, 98.7% (150/152) of subjects had trivial or no residual shunt
assessed by echocardiography. When compared with the pivotal and
continuing access studies, the PAS showed comparable outcome of
technical success and efficacy. In the combined cohort of 541 patients,
technical success at implantation was 97.4% with only 10 technical
failures. The technical failures were primarily secondary to selection
of PDAs too large to accommodate stable Nit-Occlud position. On
these occasions, the device was uniformly and easily removed prior to
deployment.








































































a OPC rate was defined previously in the pivotal study.2
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In the PAS study at the 12-month follow-up, 98.7% (150/152) of
subjects had trivial or no residual shunt assessed by echocardiography.
However, in all three studies, 95.9% of patients (n = 436) had no
detectable PDA shunting by echocardiography at 12 months with the
remainder having trivial or small shunts. Deployment of the Nit-
Occlud coil into an ideal conformation is more operator dependent
than deployment of self-expanding plug devices. For example,
implanting the reversed windings on the aortic side of the narrowest
PDA diameter with only one or one and a half loops deployed on the
pulmonary side is typically ideal. Small residual shunts are more com-
mon when more than two of the reversed windings were on the PA
side of the narrowest PDA diameter.
There are several alternative devices and coils for closure of PDA.
Amplatzer Duct Occluder (ADO) I and II (St. Jude Medical, St. Paul,
MN, USA) are FDA approved devices for the indication of PDA clo-
sure. Many other devices including the Amplatz Vascular Plug II
(St. Jude Medical) and Flipper coils (Cook Medical, Bloomington, IN)
have been used off-label for PDA closure. As such, no FDA pivotal
trial data are available for these devices.
In the pivotal trial for the ADO I, there were 393 patients. The
12-month closure rate was 98.6% and there were five (2.7%) serious
adverse events including one death.5 While direct comparisons of
these devices are not perfect given subtle differences in the trials,
clearly the closure rates are very similar. Both the ADO I and Nit-
Occlud PDA have excellent overall device characteristics and out-
comes for closure of small to moderate sized PDAs.5,6 As it is easily
retrievable and repositionable using a low profile delivery catheter,
the Nit-Occlud has very high technical success rate with minimal
residual shunt at follow-up, and is unlikely to cause obstruction in the
LPA and DAO.
4.1 | Study limitations
This study was a prospective observational study lacking a surgical or
control group using an approved PDA device. Due to the absence of
approved alternative coil-type PDA devices, the study was designed
to compare the OPC benchmark designated by the FDA advisory
panel. The PAS continues to follow-up the enrolled patients at
24 months postimplant and for 60 months for subjects with residual
PDA shunt, any significant LPA or DAO obstruction, and/or an ongo-
ing device-related issue at 12 months follow-up. Nevertheless,
authors felt it reasonable to present the interim data of PAS.
5 | CONCLUSIONS
The Nit-Occlud PDA is a safe and effective device for closure of a
small to moderate sized PDA in the PAS. At 12 months, echocardio-
graphic closure was 95.9% with device- and procedure-related SAE of
0.6%. This efficacy and safety profile was well above or comparable to
the OPC benchmark designated by the FDA advisory panel and con-
temporary practice data.7 Most importantly, there were no serious
adverse events including hemolysis, mortality or need of surgery in a
large cohort of three clinical trials and all five device embolizations
were percutaneously retrieved with a snare easily.
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